Back

Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor

28 August 2023 (15:15 - 15:45)
Organised by: Logo
Congress Presentation Part of: Experimental therapies for heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Jaya Birgitte Rosenmeier

AstraZeneca, Gothenburg (Sweden)

5 More presentations in this session

Presentation thumbnail
The acute hemodynamic effects of sodium lactate infusion: increased cardiac output and decreased afterload in a randomized trial in pigs
Mr O. Horsdal (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Non-steroidal mineralocorticoid receptor antagonist, finerenone, attenuates obesity- and hypertension-induced cardiomyocyte hypertrophy in a blood pressure-independent manner.
Doctor K. Morikawa (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
Therapeutic potential of pharmacological inhibition of programmed apoptosis, necroptosis, and ferroptosis in improving left ventricular function in post-myocardial infarction rats
Doctor C. Piamsiri (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
Effects of vericiguat on redox signaling in cardiomyocyte
Doctor T. Harada (Yufu City, JP)
Abstract Slides Video
Presentation thumbnail
Long-acting CRF2 peptide agonist improves cardiac function in a rat heart failure model
Mr Y. Stephan (Rouen, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Experimental therapies for heart failure

The Event

Event poster

ESC Congress 2023

28 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Presentation
AZD3427, a novel relaxin receptor agonist and impact on renal perfusion in patients with heart failure with reduced ejection rraction: the phase 1b Re-Perfuse study design
thumbnail
Congress Presentation
Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.
thumbnail
Congress Presentation
Daily Subcutaneous injections of Relaxin is a therapy for heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources